What is Retatrutide + Cagrilintide Blend 10mg?
QSC Retatrutide + Cagrilintide Blend combines the triple GLP-1R/GIPR/GCGR agonist retatrutide with the amylin analog cagrilintide in a single pre-formulated vial. This creates a four-mechanism research stack: GLP-1R (appetite suppression + insulin), GIPR (enhanced adipocyte and insulin effects), GCGR (hepatic fat mobilisation + thermogenesis), and amylin receptor (meal size/frequency reduction via area postrema). This represents the most mechanistically comprehensive weight loss peptide combination currently available for research — exceeding the three-pathway retatrutide monotherapy and the two-pathway CagriSema combination.
Research Applications
Quad-Mechanism Metabolic Research
Four independent receptor pathways in one vial. Research question: does amylin receptor addition to triple GLP-1/GIPR/GCGR agonism produce additive or synergistic weight reduction? Enables the deepest multi-pathway obesity pharmacology comparison.
Maximum Metabolic Suppression Model
Provides the broadest simultaneous appetite and metabolic suppression signal available in a single compound combination — useful as a “ceiling” comparator in metabolic research.
Pathway Deconstruction Research
Compare: retatrutide alone vs cagrilintide alone vs this blend — isolating the additive contribution of amylin signalling on top of triple GIP/GLP-1/glucagon agonism.
Quick Specs
| Form | Lyophilised blend, 10-vial kit |
| Purity | ≥99% HPLC per component, Janoshik COA |
| Specification | ≥99% HPLC per component, Janoshik COA |
| Storage | −20°C lyophilised; 4°C reconstituted |
| Brand | China |
